The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes
Open accessAbstract
Virtually every organism has evolved mechanisms by which, upon stimulation, lipids are released from plasma membranes and metabolized into mediators capable of changing cellular physiology. As these lipids are present at the first site exposed to external challenge, they provide an ideal substrate for the synthesis of defensive mediators and homeostatic regulators. One such group of lipid mediators is the prostanoids, including the prostaglandins (PGs) and thromboxanes (TXs). Soon after their initial isolation and characterization, the ability of prostanoids to influence inflammation and immune responses was recognized. For example, administration of prostanoids, either alone or in combination, could reproduce the cardinal signs of inflammation. Because they could induce inflammatory changes when injected into tissue and were present at high levels in inflamed lesions, prostanoids were initially categorized as proinflammatory mediators. As our understanding of prostanoid physiology has evolved, it has become clear that these mediators can act to both promote and inhibit inflammation. Thus, it is more accurate to envision these molecules as part of a complex regulatory network that modulates the actions of immune cells and the surrounding microenvironment. Their overall impact in an individual inflammatory response will depend on several factors, including the level of immune cell activation, the presence of other mediators, and the physiological state of the organism. Our ability to dissect the role of prostanoids in complex inflammatory responses has been substantially advanced by the recent development of mouse lines with targeted mutations of genes encoding enzymes and receptors in the prostanoid pathway. In this review we will develop the concept that prostanoids are both effectors and regulators of inflammation, emphasizing new information provided by these mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Inducible cyclooxygenase may have anti-inflammatory properties
Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., & Willoughby, D. A. (1999) · Nature Medicine · doi:10.1038/9550 · Cited by 1,242
Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., Mahler, J. F., Lee, C. A., Goulding, E. H., Kluckman, K. D., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90126-4 · Cited by 1,123
Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.255 · Cited by 1,099
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette, J. C., Mahler, J. F., Kluckman, K. D., Ledford, A., Lee, C. A., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90125-6 · Cited by 1,082
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Jakobsson, P.-J., Thorén, S., Morgenstern, R., & Samuelsson, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7220 · Cited by 996
Research works printed but not linked: 10
- Nishigaki, 1996, Mol Pharmacol, 50, 1031
- 10.1084/jem.180.5.1967 · doi:10.1084/jem.180.5.1967
- Ruiz, 1992, Transplantation, 54, 498, 10.1097/00007890-199209000-00021 · doi:10.1097/00007890-199209000-00021
- Kaur, 1999, Adv Exp Med Biol, 469, 409, 10.1007/978-1-4615-4793-8_59 · doi:10.1007/978-1-4615-4793-8_59
- Khan, 1995, Adv Exp Med Biol, 383, 35, 10.1007/978-1-4615-1891-4_5 · doi:10.1007/978-1-4615-1891-4_5
- 10.1172/JCI200113455 · DOI
- Audoly, 1999, Am J Physiol, 277, H924
- Hitchcock, 1978, J Pharmacol Exp Ther, 207, 630
- 10.1021/bi00016a035 · doi:10.1021/bi00016a035
- 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9 · doi:10.1002/1529-0131(200012)43:12<2687::aid-anr8>3.0.co;2-9
Cited by
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525
Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717
The Basic Science of Wound Healing
Broughton, G., Janis, J. E., & Attinger, C. E. (2006) · Plastic and Reconstructive Surgery · doi:10.1097/01.prs.0000225430.42531.c2 · Cited by 1,519
Omega-3 fatty acids and inflammatory processes: from molecules to man
Calder, P. C. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160474 · Cited by 1,456
“Eicosanoids are important regulators and mediators of inflammatory processes [7-9] and include prostaglandins (PGs), thromboxanes and leukotrienes (LTs).”
Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
Calder, P. C. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04374.x · Cited by 1,347
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
Omega-3 Fatty Acids and Inflammatory Processes
Calder, P. C. (2010) · Nutrients · doi:10.3390/nu2030355 · Cited by 1,116
Wall, R., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00287.x · Cited by 1,101
Omega-6 fatty acids and inflammation
Innes, J. K., & Calder, P. C. (2018) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.03.004 · Cited by 929
Health Implications of High Dietary Omega-6 Polyunsaturated Fatty Acids
Patterson, E., Wall, R., Fitzgerald, G. F., Ross, R. P., & Stanton, C. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/539426 · Cited by 883
Hata, A. N., & Breyer, R. M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.06.003 · Cited by 840
Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale
Calder, P. C. (2009) · Biochimie · doi:10.1016/j.biochi.2009.01.008 · Cited by 721
Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J. A., & Reddy, S. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334211100 · Cited by 638
Polyunsaturated fatty acids and inflammation
Calder, P. C. (2006) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.05.012 · Cited by 638
Platelet‐Rich Plasma: Growth Factors and Pro‐ and Anti‐Inflammatory Properties
El‐Sharkawy, H., Kantarci, A., Deady, J., Hasturk, H., Liu, H., Alshahat, M., & Van Dyke, T. E. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.060302 · Cited by 585
Genetic and pharmacological analysis of prostanoid receptor function
Narumiya, S., & FitzGerald, G. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13455 · Cited by 568
Inflammatory Disease Processes and Interactions with Nutrition
Calder, P. C., Albers, R., Antoine, J.-M., Blum, S., Bourdet-Sicard, R., Ferns, G. A., Folkerts, G., Friedmann, P. S., Frost, G. S., Guarner, F., et al. (2009) · British Journal of Nutrition · doi:10.1017/s0007114509377867 · Cited by 568
The gene encoding phosphodiesterase 4D confers risk of ischemic stroke
Gretarsdottir, S., Thorleifsson, G., Reynisdottir, S. T., Manolescu, A., Jonsdottir, S., Jonsdottir, T., Gudmundsdottir, T., Bjarnadottir, S. M., Einarsson, O. B., Gudjonsdottir, H. M., et al. (2003) · Nature Genetics · doi:10.1038/ng1245 · Cited by 564
Sensitization of TRPV1 by EP1 and IP Reveals Peripheral Nociceptive Mechanism of Prostaglandins
Moriyama, T., Higashi, T., Togashi, K., Iida, T., Segi, E., Sugimoto, Y., Tominaga, T., Narumiya, S., & Tominaga, M. (2005) · Molecular Pain · doi:10.1186/1744-8069-1-3 · Cited by 544
Fatty acids and inflammation: The cutting edge between food and pharma
Calder, P. C. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.085 · Cited by 516
Scandella, E., Men, Y., Gillessen, S., Förster, R., & Groettrup, M. (2002) · Blood · doi:10.1182/blood-2001-11-0017 · Cited by 500
n−3 Polyunsaturated fatty acids and inflammation: From molecular biology to the clinic
Calder, P. C. (2003) · Lipids · doi:10.1007/s11745-003-1068-y · Cited by 499
Essential fatty acids as functional components of foods- a review
Kaur, N., Chugh, V., & Gupta, A. K. (2014) · Journal of Food Science and Technology · doi:10.1007/s13197-012-0677-0 · Cited by 490
Dietary modification of inflammation with lipids
Calder, P. C. (2002) · Proceedings of the Nutrition Society · doi:10.1079/pns2002166 · Cited by 485
Hasturk, H., Kantarci, A., Goguet-Surmenian, E., Blackwood, A., Andry, C., Serhan, C. N., & Van Dyke, T. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.7021 · Cited by 461
Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases
Calder, P. C. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700289 · Cited by 457
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Very long-chain n -3 fatty acids and human health: fact, fiction and the future
Calder, P. C. (2018) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117003950 · Cited by 419
Immune modulation by parenteral lipid emulsions
Wanten, G. J., & Calder, P. C. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.5.1171 · Cited by 416
Platelets: signaling cells in the immune continuum
Weyrich, A. S., & Zimmerman, G. A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.07.003 · Cited by 414
Cytosolic phospholipase A2: physiological function and role in disease
Leslie, C. C. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r057588 · Cited by 413
Knockouts model the 100 best-selling drugs—will they model the next 100?
Zambrowicz, B. P., & Sands, A. T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd987 · Cited by 393
n -3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions
Calder, P. C. (2013) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113001031 · Cited by 364
Aronoff, D. M., Canetti, C., & Peters-Golden, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.559 · Cited by 360
Chen, M., Divangahi, M., Gan, H., Shin, D. S. J., Hong, S., Lee, D. M., Serhan, C. N., Behar, S. M., & Remold, H. G. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080767 · Cited by 357
Omega-3 fatty acids and depression: scientific evidence and biological mechanisms
Grosso, G., Galvano, F., Marventano, S., Malaguarnera, M., Bucolo, C., Drago, F., & Caraci, F. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/313570 · Cited by 351
“Omega-3 EPA and DHA incorporation in cell membrane decreases their AA content and reduces the amount of substrate available to produce inflammatory and immunoregulatory eicosanoids [131].”
BackgroundMiles, E. A., & Calder, P. C. (2012) · British Journal of Nutrition · doi:10.1017/s0007114512001560 · Cited by 352
Wang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 349
Ishibashi, J., & Seale, P. (2010) · Science · doi:10.1126/science.1190816 · Cited by 338
BENBARUCH, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.006 · Cited by 335
Anti-Inflammatory Treatments for Chronic Diseases: A Review
Laveti, D., Kumar, M., Hemalatha, R., Sistla, R., Naidu, V., Talla, V., Verma, V., Kaur, N., & Nagpal, R. (2013) · Inflammation & Allergy-Drug Targets · doi:10.2174/18715281113129990053 · Cited by 325
Fredberg, U., & Stengaard‐Pedersen, K. (2008) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2007.00746.x · Cited by 322
Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum
Vieira-de-Abreu, A., Campbell, R. A., Weyrich, A. S., & Zimmerman, G. A. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0286-4 · Cited by 321
The lung as a privileged site for the beneficial actions of PGE2
Vancheri, C. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.001 · Cited by 313
Fatty Acid Binding Proteins—The Evolutionary Crossroads of Inflammatory and Metabolic Responses
Makowski, L., & Hotamisligil, G. S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.9.2464s · Cited by 311
Natural anti-inflammatory agents for pain relief
Bost, J., Maroon, A., & Maroon, J. (2010) · Surgical Neurology International · doi:10.4103/2152-7806.73804 · Cited by 292
Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse
Nataraj, C., Thomas, D. W., Tilley, S. L., Nguyen, M., Mannon, R. B., Koller, B. H., & Coffman, T. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13640 · Cited by 287
Self-citationInduction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals
Eliopoulos, A. G. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf478 · Cited by 284
Signaling and regulation of G protein-coupled receptors in airway smooth muscle
Billington, C. K., & Penn, R. B. (2003) · Respiratory Research · doi:10.1186/1465-9921-4-2 · Cited by 284
Dietary docosahexaenoic and eicosapentaenoic acid: Emerging mediators of inflammation
Chapkin, R. S., Kim, W., Lupton, J. R., & McMurray, D. N. (2009) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.05.010 · Cited by 282
Dietary α-linolenic acid and health-related outcomes: a metabolic perspective
Burdge, G. C., & Calder, P. C. (2006) · Nutrition Research Reviews · doi:10.1079/nrr2005113 · Cited by 281
Early nutrition and immunity - progress and perspectives.
Calder, P. C., Krauss‐Etschmann, S., de Jong, E. C., Dupont, C. M., Frick, J.-S., Frøkiær, H., Heinrich, J., Garn, H., Koletzko, S., Lack, G., et al. (2006) · PubMed · doi:10.1017/bjn20061917 · Cited by 268
Burian, M., & Geisslinger, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.004 · Cited by 259
Hervé, M., Angeli, V., Pinzar, E., Wintjens, R., Faveeuw, C., Narumiya, S., Capron, A., Urade, Y., Capron, M., Riveau, G., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324143 · Cited by 256
Calder, P. C. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100710 · Cited by 255
“These are long recognised mediators and regulators of inflammation and immunity and include prostaglandins (PG), thromboxanes, leukotrienes (LT) and other oxidised derivatives produced by the cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 pathways [23, 24].”
BackgroundPassos, G. F., Fernandes, E. S., da Cunha, F. M., Ferreira, J., Pianowski, L. F., Campos, M. M., & Calixto, J. B. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.09.032 · Cited by 250
Environmental immune disruptors, inflammation and cancer risk
Thompson, P. A., Khatami, M., Baglole, C. J., Sun, J., Harris, S. A., Moon, E.-Y., Al-Mulla, F., Al-Temaimi, R., Brown, D. G., Colacci, A. M., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv038 · Cited by 227
“All four of the EP receptors are present on the majority of cells involved in immune responses (26,27).”
BackgroundKremmyda, L.-S., Vlachava, M., Noakes, P. S., Diaper, N. D., Miles, E. A., & Calder, P. C. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8186-2 · Cited by 198
“Eicosanoid mediators are involved in modulating the intensity and duration of inflammatory responses [see [15, 16] for reviews].”
BackgroundStapleton, R. D., Martin, T. R., Weiss, N. S., Crowley, J. J., Gundel, S. J., Nathens, A. B., Akhtar, S. R., Ruzinski, J. T., Caldwell, E., Curtis, J. R., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318218669d · Cited by 173
Lipids in the intensive care unit: Recommendations from the ESPEN Expert Group
Calder, P. C., Adolph, M., Deutz, N. E., Grau, T., Innes, J. K., Klek, S., Lev, S., Mayer, K., Michael-Titus, A. T., Pradelli, L., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.08.032 · Cited by 158
PPAR and Immune System-What Do We Know?
Zhang, X., & Young, H. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00057-7 · Cited by 123
Grau-Carmona, T., Morán-García, V., García-de-Lorenzo, A., Heras-de-la-Calle, G., Quesada-Bellver, B., López-Martínez, J., González-Fernández, C., Montejo-González, J. C., Blesa-Malpica, A., Albert-Bonamusa, I., et al. (2011) · Clinical Nutrition · doi:10.1016/j.clnu.2011.03.004 · Cited by 121
Calder, P. C. (2008) · Proceedings of The Nutrition Society · doi:10.1017/s0029665108008690 · Cited by 111
“Eicosanoids are key mediators and regulators of inflammation((6,7)) and are generated from C20 PUFA.”
BackgroundCalder, P. C. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.11.003 · Cited by 81
Pharmacologic Inhibition of COX-1 and COX-2 in Influenza A Viral Infection in Mice
Carey, M. A., Bradbury, J. A., Rebolloso, Y. D., Graves, J. P., Zeldin, D. C., & Germolec, D. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011610 · Cited by 77
Butyrate modulates gene and protein expression in human intestinal endothelial cells
Ogawa, H., Rafiee, P., Fisher, P. J., Johnson, N. A., Otterson, M. F., & Binion, D. G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.026 · Cited by 70
Arras, M., Louahed, J., Simoen, V., Barbarin, V., Misson, P., van den Brûle, S., Delos, M., Knoops, L., Renauld, J.-C., Lison, D., et al. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0383oc · Cited by 46
Weiss, R., Schilling, E., Grahnert, A., Kölling, V., Dorow, J., Ceglarek, U., Sack, U., & Hauschildt, S. (2015) · Innate Immunity · doi:10.1177/1753425915602545 · Cited by 41
Famta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01669-9 · Cited by 21
Paccani, S. R., Patrussi, L., Ulivieri, C., Masferrer, J. L., D'Elios, M. M., & Baldari, C. T. (2005) · Blood · doi:10.1182/blood-2004-04-1299 · Cited by 17
Metadata
- Authors
- Tilley, S. L., Coffman, T. M., & Koller, B. H.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-07-01
- Volume
- 108
- Issue
- 1
- Pages
- 15-23
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2028089693
- Cited by
- 725
- References
- 44
- FWCI
- 24.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.